Odronextamab for Relapsed/Refractory Large B-cell Lymphomas Before Definitive Lymphoma-Directed Therapies
Latest Information Update: 23 Jan 2025
Price :
$35 *
At a glance
- Drugs Odronextamab (Primary) ; CAR-T cell therapies
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- 23 Jan 2025 New trial record